A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care ...

Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a ...

Against the backdrop of a Cas9 patent battle that refuses to die, Editas Medicine is cashing in a chunk of the licensing ...

Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the ...

Siemens Healthineers has received a new go-ahead from the FDA for what the company describes as its first completely ...

The digital pathology developer Proscia is launching an artificial intelligence toolkit for life science researchers, ...

One of those companies, a contract research organization focused on genetic medicines called Franklin Biolabs, officially ...

Kurma plans to raise a total of 250 million euros ($276 million) for the fund, dubbed Biofund IV, which would make it the ...

Pentixapharm has brought in almost 20 million euros ($22 million) from an IPO, with the German biotech earmarking the ...

Legend Biotech appears to be on a mission to shake up its cell therapy development. | A week after signing up to collaborate ...

Septerna is about to find out how a biotech without “any meaningful clinical data” fares in the late 2024 IPO market. | ...

GigaGen’s prior work with the DOD produced polyclonal antibodies that can neutralize two botulinum neurotoxins, which are ...